Indaptus Therapeutics, Inc. (NASDAQ:INDP)
| Market Cap | 289.90M-9.5% |
| Revenue (ttm) | 0 |
| Net Income | -15.42M+9.1% |
| EPS | -0.14+81.5% |
| Shares Out | 113.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,159,590 |
| Open | 2.00 |
| Previous Close | 2.08 |
| Day's Range | 1.97 - 2.63 |
| 52-Week Range | 0.92 - 8.57 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 17, 2026 |
About INDP
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
$INDP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INDP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INDP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INDP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
INDP Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Internal personnel costs | $45.15K | 76.33% |
| Other income, net | $14.00K | 23.67% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New INDP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INDP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INDP
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $43.41K |
Estimated from each fund’s disclosed top holdings × AUM
INDP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from INDP’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.